Companies › DualityBio
10 active drug programs in 14 registered trials: 9 Phase 1, 3 Phase 2, 2 Phase 3; Oncology, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DB-1303/BNT323 HER2-targeting bispecific antibody | ERBB2 | Phase 3 | HER2-positive Breast Cancer; Metastatic Breast Cancer; HER2-positive Advanced Solid Tumor | Aug 2027 |
| BNT327 Personalized neoantigen vaccine | – | Phase 2 | Solid Tumors; Advanced Solid Tumor | Aug 2027 |
| DB-1305 OX40 agonist | – | Phase 2 | Solid Tumors; Advanced Solid Tumor | Aug 2027 |
| DB-1311 | – | Phase 2 | Solid Tumors | Jun 2030 |
| DB-1419 | – | Phase 1 | Solid Tumor, Adult | Feb 2027 |
| DB-2304 | – | Phase 1 | Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus | Jun 2027 |
| DB-1311/BNT324 | – | Phase 1 | Advanced Solid Tumors | Dec 2027 |
| DB-1310 | – | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| DB-1317 | – | Phase 1 | Advanced/Metastatic Solid Tumors | Jun 2028 |
| DB-1324 | – | Phase 1 | Gastrointestinal Cancer | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06554795 | DB-1419 | Phase 1 | Solid Tumor, Adult | Oncology | Feb 2027 |
| NCT06625671 | DB-2304 | Phase 1 | Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus | Immunology | Jun 2027 |
| NCT05438329 | BNT327 | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2027 |
| NCT05438329 | DB-1305 | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2027 |
| NCT05150691 | DB-1303/BNT323 | Phase 1 | HER2-positive Advanced Solid Tumor | Oncology | Aug 2027 |
| NCT06265428 | DB-1303/BNT323 | Phase 3 | HER2-positive Breast Cancer | Oncology | Dec 2027 |
| NCT05914116 | DB-1311/BNT324 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT05785741 | DB-1310 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT07141706 | DB-1317 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Jun 2028 |
| NCT06018337 | DB-1303/BNT323 | Phase 3 | Metastatic Breast Cancer | Oncology | Aug 2028 |
| NCT07263594 | DB-1324 | Phase 1 | Gastrointestinal Cancer | Oncology | Dec 2028 |
| NCT06953089 | DB-1311 | Phase 2 | Solid Tumors | Oncology | Jun 2030 |
| NCT06953089 | BNT327 | Phase 2 | Solid Tumors | Oncology | Jun 2030 |
| NCT06953089 | DB-1305 | Phase 2 | Solid Tumors | Oncology | Jun 2030 |
SystImmune Aston Sci. Chengdu SciMount Pharmatech Shanghai Miracogen BioRay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.